MedTrace Logo

Lubricin-inspired Osteoarthritis Treatment: a Unique Solution

NCT07611708 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-05-29

No results posted yet for this study

Summary

This goal of this open label study is to evaluate the safety and tolerability of a single intra-articular administration of ABR1 in adults with knee osteoarthritis with a KL grade from 2 to 4. The primary questions it aims to answer are:

1. Is ABR1 safe to use as an intraarticular injection for participants with knee osteoarthritis?
2. What medical problems do participants have after receiving a single injection of ABR1?

Participants will receive a single injection of ABR1 to the knee with osteoarthritis. Participants will

1. Keep a stable pain treatment regimen
2. Visit the clinic at 1 week, 4 weeks, 8 weeks, and 12 weeks post injection
3. Keep a diary of their symptoms and number of times they use a rescue medication for their knee pain.

Conditions

  • Osteo Arthritis of the Knee

Interventions

DEVICE

ABR1

Received a single dose of ABR1

Sponsors & Collaborators

  • Pleryon Therapeutics (Hangzhou) Limited

    lead INDUSTRY

Principal Investigators

  • Charis Lau, PharmD, OD, MBA · Pleryon Therapeutics Limited

  • David Hunter, MD · Royal North Shore Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2027-06-30
Completion
2027-12-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07611708 on ClinicalTrials.gov